Allogenetics

engineering health

Allogenetics GmbH is a Hannover-based biotechnology company founded in 2022 as a spin-off from Hannover Medical School (MHH). The company is developing a first-in-class extracorporeal precision genetic engineering platform to render donor organs immunologically “invisible.” Its lead preclinical candidate, ALG-115, silences donor MHC expression ex vivo, aiming to eliminate lifelong systemic immunosuppression and fundamentally transform solid organ transplantation.